Patient-Reported Outcomes and Changes in PSA in Patients With Advanced Prostate Cancer Treated With Apalutamide in the SPARTAN and TITAN Studies - OncLive

-

Expert urologist Benjamin Lowentritt, MD, reviews advanced prostate cancer data from the SPARTAN and TITAN studies comparing patient-reported outcomes to changes in PSA.

Transcript:

Background

  • In phase 3 placebo-controlled trials using androgen deprivation therapy (ADT), the addition of apalutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCRPC) resulted in the following:
    • Improved overall survival
    • Reduced risk of disease progression
    • Preserved health-related quality of life
  • In many patients, prostate-specific antigen (PSA) responses were rapid and deep, with reduction to 0.2 ng/mL or less or 90% or greater reduction compared with baseline.
  • Reduction was associated with extended metastasis-free survival or radiographic progression-free survival.
  • The objective of this post hoc analysis of the SPARTAN (NCT01946204) and TITAN (NCT02489318) trials was to explore the relationship between rapid and deep PSA decline with health-related quality of life following apalutamide treatment.

Methods

  • Patients were randomized to 28-day cycles of apalutamide 240 mg every day or placebo.
  • Patient-reported outcomes were assessed at baseline, specific cycles during treatment, and postprogression up to 1 year via paper or electronic surveys.
  • A month 3 landmark analysis and a month 6 landmark analysis evaluated PSA decline and time to subsequent deterioration in patient-reported outcomes.
  • Time-to-event end points were analyzed by Kaplan-Meier method and Cox proportional hazards model

Results and Conclusions

  • At months 3 and 6, PSA decline correlated with health-related quality of life measures.
  • Patients with advanced prostate cancer who had rapid and deep declines in PSA following treatment with apalutamide had more favorable health-related quality of life, physical wellbeing, and less pain and fatigue.
  • These data show that early PSA response indicates benefits in patient-relevant end points in conjunction with oncological outcomes.
  • These data may help guide care and counsel for patients with nmCRPC or mCSPC.

Comments

Post a Comment

Popular posts from this blog

Sentinel lymph node biopsy: What cancer patients should know

-
Image
cancer lump on neck :: Article Creator Doctor Watching TV Show Spotted Cancer On Show's Guest That She Didn't Know About Say what you will about social media and daytime TV, but sometimes, they can help work wonders. In fact, the power of Facebook and the popularity of HGTV's Beachfront Bargain Hunt played a big part in helping Nicole McGuiness get ahead of her serious cancer diagnosis - but it was an eagle-eyed doctor who really saved her bacon. The then-32-year-old appeared on the property series alongside her father while in search of a holiday home in North Carolina to celebrate her recent recovery from brain cancer in May 2018. She explained that she had set her sights on 'something near the water', specifically a beachfront property in Morehead City, to start afresh in this new phase of her life. Dr. Erich Voigt was one of the viewers who tuned into the Beachfront Bargain Hunt episode, which Nicole featured in, an...
Read more

Q&A

-
Image
prostate calcification treatment :: Article Creator Treatment Options For Different Stages Of Prostate Cancer Have you or a loved one been diagnosed with prostate cancer? Understanding the various treatment options available for different stages of this disease can empower you to make informed decisions. Navigating the journey through prostate cancer treatment starts with gaining knowledge about how the disease is categorized and what treatments align with each stage. Whether dealing with an early diagnosis or tackling more advanced stages, a spectrum of approaches is designed to manage the disease effectively. This information provides clarity and hope, showcasing the advancements in medical science that are helping individuals lead healthier lives post-diagnosis. Patients and their families need to engage in open discussions with healthcare professionals to understand each treatment option's potential outcomes and side effects. With this...
Read more

What Type of Cancer Causes Low Hemoglobin (Anemia)?

-
Image
diagnostic cancer pancreas :: Article Creator Unlocking Insights Into Pancreatic Cancer And Cachexia In an interview with Targeted Oncology, Sanjay Goel, MD, MS, discussed the mystery of cachexia in pancreatic cancer and why it remains a challenging symptom to target. As 1 of the most lethal cancers, pancreatic cancer remains a disease warranting research and clinical studies. While the lack of targetable mutations and tumor microenvironment make treating pancreatic cancer difficult, 1 of the most challenging symptoms is unrelated to the tumor: cachexia, or more colloquially, wasting syndrome. Cachexia leads to significant muscle mass loss and contributes to poor outcomes in pancreatic cancer treatment. "It's characterized by significant losses in muscle mass, and it's not purely a nutritional deficiency. There are people who believe that overall cachexia is responsible for the deaths of maybe even up to half of all the patien...
Read more